CytomX Therapeutics Inc (NASDAQ:CTMX) currently has a daily average trading volume of 928.95K but it saw 204763882 shares traded in last market. With a market cap of 347.40M USD, the company’s current market price of $5.13 came rising about 214.72 while comparing to the previous closing price of $1.63. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.86 and as low as $1.04.
Taking a look at 20-day trading activity of CytomX Therapeutics Inc (CTMX) gives us an average price of $2.0100, while its current price level is 79.68% below from 52-week high level whereas it is 393.27% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.1200 while that of 200 days or SMA-200 reads an average of $1.6100. A closer look into the stock’s movement over the week reveals that its volatility is standing at 25.37% during that period while stretching the period over a month that decreases to 10.94%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 89.88 which implies that the stock is in overbought territory.
BMO Capital Markets downgraded its recommendation for the stock as a “Market Perform” from “Outperform” on November 14, 2022 while assigning a price target range of $3-$2.60. Wedbush issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $6 and $2.
Over the week, CTMX’s stock price is moving 214.72% up while it is 139.72% when we observe its performance for the past one month. Year-to-date it is 230.97% up and over the past year, the stock is showing an upside performance of 198.26%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.05 beat the consensus estimate of -0.11 for the same. In next quarter, company is expected to be making quarterly sales of $21.43M as analysts are expecting the sales for current fiscal year at $88.44M and seeing the company making $77.9M in sales next year. Moreover, analysts are in estimates of $22.02M for current-quarter revenue.
Currently, CytomX Therapeutics Inc’s total number of outstanding shares is 67.31M. Stock’s beta reads 1.08. Stock has a price to sale or P/S ratio amounts to 3.43. Its return on asset (ROA) is -0.24% on average.
